Reply: Tofacitinib is a step forward for management of patients with interstitial lung disease associated with anti-MDA5-positive dermatomyositis

We are pleased that our recent publication, “Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study”, has attracted significant interest in the fields of respiratory medicine and rheumatology [1]. We sincerely appreciate the thoughtful correspondences from Y. Uzunhan and B. Hervier, and C-W. Tseng and J.C-C. Wei, and are privileged to address their comments below.